XBRYK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XBRYK (XBRYK).
XBRYK is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), forming a covalent bond with Cys481 in the BTK active site, thereby inhibiting B-cell receptor signaling and downstream pathways essential for B-cell proliferation and survival.
| Metabolism | Primarily metabolized by CYP3A4; minor contributions from CYP2D6 and CYP2C19. |
| Excretion | Primarily renal (approx. 70% unchanged drug) with biliary/fecal contribution (approx. 30% as metabolites). |
| Half-life | Terminal half-life is 3.5 hours (range 3–4 hours), necessitating multiple daily dosing for sustained effect. |
| Protein binding | Approximately 85% bound to albumin. |
| Volume of Distribution | 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 80–85% (high first-pass metabolism, but extensive absorption). |
| Onset of Action | Oral: 30–60 minutes; IV: immediate (<5 minutes). |
| Duration of Action | Oral: 4–6 hours; IV: 6–8 hours for analgesic effect; shorter for antipyresis. |
12 mg subcutaneously every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min. |
| Liver impairment | No dose adjustment required for Child-Pugh Class A or B; not studied in Class C. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XBRYK (XBRYK).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio is unknown but drug is likely excreted into human milk based on molecular weight and lipophilicity. Potential for serious adverse reactions in nursing infants, including tumorigenicity. Advise to discontinue breastfeeding or abstain from therapy. |
| Teratogenic Risk | Pregnancy Category X. Contraindicated in pregnancy due to proven teratogenicity in animal studies and human reports. First trimester: high risk of major congenital malformations (neural tube defects, cardiac anomalies). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal toxicity. Effective contraception required before, during, and after treatment. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concurrent use with strong CYP3A4 inducers (e.g., rifampin, St. John's wort) due to potential for reduced efficacy."]
| Precautions | ["Hemorrhage: Fatal bleeding events have occurred; monitor for signs of bleeding, consider risk-benefit in patients on anticoagulants or antiplatelet agents.","Infections: Serious infections (including opportunistic infections) have occurred; monitor for signs and symptoms.","Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia observed; monitor blood counts regularly.","Cardiac arrhythmias: Atrial fibrillation and flutter reported; monitor patients with cardiac risk factors.","Second primary malignancies: Non-melanoma skin cancer and other malignancies have occurred.","Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of effective contraception."] |
Loading safety data…
| Fetal Monitoring | Confirm negative pregnancy test before initiation. Monthly pregnancy tests during therapy. Fetal ultrasound for anomalies at 18-20 weeks gestation if accidental exposure occurs. Monitor for maternal hepatotoxicity, myelosuppression, and electrolyte imbalances. Assess fetal growth in third trimester if exposure late in pregnancy. |
| Fertility Effects | Impairs fertility in both sexes. In males: may cause oligospermia, azoospermia, and testicular atrophy with potential irreversibility. In females: may cause anovulation, menstrual irregularities, and premature ovarian failure. Advise fertility preservation options (sperm or oocyte cryopreservation) before treatment. |